The influence of genetic polymorphisms on population variability in six xenobiotic-metabolizing enzymes
Ginsberg, G; Smolenski, S; Neafsey, P; Hattis, D; Walker, K; Guyton, KZ; Johns, DO; Sonawane, B
HERO ID
196821
Reference Type
Journal Article
Subtype
Review
Year
2009
Language
English
PMID
| HERO ID | 196821 |
|---|---|
| Material Type | Review |
| In Press | No |
| Year | 2009 |
| Title | The influence of genetic polymorphisms on population variability in six xenobiotic-metabolizing enzymes |
| Authors | Ginsberg, G; Smolenski, S; Neafsey, P; Hattis, D; Walker, K; Guyton, KZ; Johns, DO; Sonawane, B |
| Journal | Journal of Toxicology and Environmental Health, Part B: Critical Reviews |
| Volume | 12 |
| Issue | 5 |
| Page Numbers | 307-333 |
| Abstract | This review provides variability statistics for polymorphic enzymes that are involved in the metabolism of xenobiotics. Six enzymes were evaluated: cytochrome P-450 (CYP) 2D6, CYP2E1, aldehyde dehydrogenase-2 (ALDH2), paraoxonase (PON1), glutathione transferases (GSTM1, GSTT1, and GSTP1), and N-acetyltransferases (NAT1 and NAT2). The polymorphisms were characterized with respect to (1) number and type of variants, (2) effects of polymorphisms on enzyme function, and (3) frequency of genotypes within specified human populations. This information was incorporated into Monte Carlo simulations to predict the population distribution and describe interindividual variability in enzyme activity. The results were assessed in terms of (1) role of these enzymes in toxicant activation and clearance, (2) molecular epidemiology evidence of health risk, and (3) comparing enzyme variability to that commonly assumed for pharmacokinetics. Overall, the Monte Carlo simulations indicated a large degree of interindividual variability in enzyme function, in some cases characterized by multimodal distributions. This study illustrates that polymorphic metabolizing systems are potentially important sources of pharmacokinetic variability, but there are a number of other factors including blood flow to liver and compensating pathways for clearance that affect how a specific polymorphism will alter internal dose and toxicity. This is best evaluated with the aid of physiologically based pharmacokinetic (PBPK) modeling. The population distribution of enzyme activity presented in this series of articles serves as inputs to such PBPK modeling analyses. |
| Doi | 10.1080/10937400903158318 |
| Pmid | 20183525 |
| Wosid | WOS:000271375100001 |
| Is Certified Translation | No |
| Dupe Override | No |
| Comments | Journal: Journal of Toxicology and Environmental Health, Part B ISSN: |
| Is Public | Yes |
| Language Text | English |